Emmaus Life Sciences, Inc. (EMMA)

Emmaus Life Sciences Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	2.55	2.55	2.02	2.28	2.49	1.77
Short-Term Investments	0	0	-19.97	0	0	27.93
Cash & Cash Equivalents	2.55	2.55	2.02	2.28	2.49	29.7
Cash Growth	26.03%	26.03%	-11.32%	-8.36%	-91.63%	812.47%
Receivables	5.52	5.52	0.38	1.04	0.2	2.15
Inventory	1.71	1.71	2.38	4.39	7.09	7.97
Other Current Assets	1.73	1.73	21.49	1.38	1.49	1.4
Total Current Assets	11.51	11.51	6.29	9.09	11.26	41.22
Property, Plant & Equipment	2.4	2.4	2.87	3.63	4.19	4.63
Long-Term Investments	20.98	20.98	38.8	17.62	15.66	13.33
Other Long-Term Assets	0.3	0.3	0.26	26.4	28.16	0.29
Total Long-Term Assets	23.67	23.67	41.94	47.64	48.02	18.24
Total Assets	35.18	35.18	48.23	56.73	59.28	59.46
Accounts Payable	5.89	5.89	3.79	2.58	2.02	7.28
Deferred Revenue	10	10	10	6.61	5.44	4.22
Current Debt	29.04	29.04	24.72	22	12.15	15.54
Other Current Liabilities	16.58	16.58	15.82	5.91	3.78	5.79
Total Current Liabilities	61.51	61.51	54.32	37.1	23.38	32.83
Long-Term Debt	2.23	2.23	0.38	7.91	6.84	3.93
Other Long-Term Liabilities	19.2	19.2	27.61	33.17	34.47	33.75
Total Long-Term Liabilities	21.43	21.43	27.99	41.08	41.31	37.68
Total Liabilities	82.94	82.94	82.32	78.18	64.69	70.51
Total Debt	33.1	33.1	25.1	29.92	18.99	19.48
Debt Growth	7.41%	31.89%	-16.11%	57.56%	-2.51%	3194.70%
Common Stock	0.06	0.06	0.05	0.05	0.05	0.05
Retained Earnings	-256.12	-256.12	-252.34	-241.27	-225.33	-226.23
Comprehensive Income	-17.03	-17.03	-2.62	-0.26	1.14	-0.08
Shareholders' Equity	-47.76	-47.76	-34.09	-21.45	-5.42	-11.05
Total Liabilities and Equity	35.18	35.18	48.23	56.73	59.28	59.46
Net Cash / Debt	-30.55	-30.55	-43.05	-27.64	-16.5	10.22
Net Cash / Debt Growth	-	-	-	-	-	283.80%
Net Cash Per Share	-0.49	-0.58	-0.87	-0.56	-0.34	0.24
Working Capital	-50	-50	-48.03	-28.01	-12.13	8.39
Book Value Per Share	-0.77	-0.90	-0.69	-0.44	-0.11	-0.26

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.